BioCentury
ARTICLE | Emerging Company Profile

Arsanis: Antibodies for infection

Arsanis developing antibodies for bacterial diseases, nosocomial infections

April 2, 2012 7:00 AM UTC

By targeting conserved sequences of bacterial proteins as well as bacterial toxins, Arsanis Inc. expects its antibody cocktails to improve outcomes in infections that are resistant to conventional antibiotics.

Arsanis was created when its three founders, one from Intercell AG, and two from Adimab LLC, realized they had complementary goals...